Endocrine therapies for sarcopenia in older men.
This review looks at new therapeutic developments for the increasingly recognized problem of sarcopenia. Increased adiposity and reduced lean body mass characterize ageing men. The potential therapeutic role of the growth hormone/insulin-like growth factor axis, androgen modulators and myostatin inhibition are discussed.
Solomon
Andrew
A
Department of Endocrinology, Royal Free Hospital and Medical School, London.
Bouloux
Pierre
P
D000368:Aged; D000375:Aging; D000728:Androgens / Q000627:therapeutic use; D015444:Exercise / Q000502:physiology; D013006:Growth Hormone / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009133:Muscular Atrophy / Q000188:drug therapy*; D055435:Myostatin; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D016896:Treatment Outcome
D000728:Androgens; D006728:Hormones; C525911:MSTN protein, human; D055435:Myostatin; D016212:Transforming Growth Factor beta; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone